Tempus AI Gets a $70 BTIG Reset: Buy Rating Stays, but a $46 Risk Door Is Opening

BTIG Keeps Buy on Tempus, but the Target Cut Raises the Stakes

BTIG kept its Buy rating, but the call just got less forgiving after the firm cut its target to $70 from $80. From recent levels, that still implies roughly 49.64% potential upside, which is why the Buy label still matters. At the same time, the buffer for disappointment got smaller.

Tempus still has a real operating case. Q2 revenue rose 22% year over year, and management raised 2026 guidance to a 25% to 26% growth range. The first full post-Ambry quarter looks more like setup for that higher outlook than a one-off print.

Why the stock is in focus now

The tension is whether the market keeps rewarding that growth or starts treating the shares mainly as deal collateral. Tempus's announced Personalis acquisition includes a provision that could let Personalis walk away if the stock stays too far below $46 per share, and shares have been hovering near that area. So the near-term debate is not just about growth quality. It is also about whether the stock can hold a level that supports management's biggest strategic move.

Tempus Q2 Results Show Growth, But Underlying Profitability Still Needs Time

The operating trends are improving

Tempus reported $382.5 million in revenue, while diagnostics revenue rose 20% and Data and Apps increased 28%. Those numbers suggest both major engines are still contributing.

Oncology is the clearest example. Oncology volume growth reached 31% year over year, and MRD volume was 9,000 tests. BTIG said those early MRD initiatives are ramping up and could become a larger part of the Tempus thesis over time.

Where the economics could improve

There is also a plausible path to better mix and margins, even if reported earnings still look uneven. FDA approval of tumor-only xT CDx would let Tempus migrate the entire solid tumor DNA portfolio to ADLT pricing beginning in 2027. Management has also pointed to roughly $400 million of revenue uplift by 2028 from the combined approval path. If more testing moves into higher-value categories, Tempus does not just sell more tests; it can also improve the quality of that revenue.

The data side matters too. Tempus signed about $200 million in new Data and Applications licenses, reinforcing the faster-growing software side of the business.

Why the income statement still looks messy

The quarter was not purely a good-news story. Outside commentary noted that most of the Q2 GAAP net income came from revaluing Tempus's existing stake in Personalis, and that the underlying operating loss still widened. In other words, the business mechanics look healthier, but the income statement still needs time to reflect that improvement cleanly.

The $46 Termination Line Is the Real Near-Term Risk

BTIG's target cut matters, but the sharper repricing risk is structural.

Why the stock price now matters for the deal

Tempus's proposed $1.5 billion Personalis acquisition is no longer just a strategic headline. The agreement includes a clause that lets Personalis terminate if Tempus shares trade below $46 per share. At the time of BTIG's note, the stock was around $46.80, so the termination threshold was close enough to matter.

That changes the setup in a few ways:

• The stock starts to function as deal collateral, not just a proxy for long-term growth.
• Investors can focus less on whether Tempus deserves a higher multiple and more on whether it can keep the deal on track.
• If concerns about the $46 line spread while the stock is still near it, sentiment can move faster than fundamentals.

What Would Support BTIG's $70 Target From Here

With BTIG still Buy, the $70 target is less about market mood and more about whether the next few quarters show a better business mix.

What would make $70 more believable

The next test is not one strong quarter. It is sustained improvement across the same metrics already in evidence: diagnostics revenue rose 20%, Data and Apps grew faster, oncology volume growth accelerated, and MRD volume is already being tracked at 9,000 tests. The bigger valuation lever is still pricing and mix. xT Tumor Only migration to ADLT pricing beginning in 2027 plus additional approval and reimbursement progress would help the case materially.

What would weaken the thesis

The clearest watchpoints are also straightforward: is the Personalis fit showing up in MRD traction, or is the story still mostly strategic? Personalis MRD technology adds a clear complement to Tempus's commercial scale and platform, but that only supports a higher target if adoption and mix continue to improve. If oncology momentum cools, data growth stalls, or the pricing path slips, BTIG's cut may start to look conservative rather than cautious.